(Q38167010)

30 August 2017

title

Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus (English)

1 reference

30 August 2017

1 reference

Courtney I Jarvis

1

1 reference

30 August 2017

Adriana Cabrera

series ordinal

2

1 reference

30 August 2017

Derek Charron

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 November 2013

1 reference

Annals of Pharmacotherapy

30 August 2017

published in

1 reference

30 August 2017

volume

47

1 reference

30 August 2017

issue

11

1 reference

30 August 2017

page(s)

1532-1539

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Recent advances in incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504076

21 January 2018

Identifiers

DOI

10.1177/1060028013504076

1 reference

30 August 2017

1 reference